Advertisement

IIT Madras To Collaborate With Adyar Cancer Institute To Develop Kit For Early Diagnosis Of Ovarian Cancer

The technology developed from this collaboration with be transferred to a suitable Industrial partner who will manufacture and market the testing kit to the general public

 Indian Institute of Technology Madras is going to collaborate with the Cancer Institute (WIA) at Adyar in Chennai, Tamil Nadu, to develop a point-of-care device for the early diagnosis of Ovarian Cancer.

The two institutions have entered into an MoU to further develop and validate this technology and transfer it to a suitable Industrial partner to manufacture and market the kit to the general public.

The MoU towards this collaboration was signed on 29th July 2021 by Dr Selvaluxmi, Director, Cancer Institute, and Prof. Ravindra Gettu, Dean Industrial Consultancy and Sponsored Research, IIT Madras, the lead investigators Dr V.V. Raghavendra Sai, Associate Professor (Biomedical Engineering), Department of Applied Mechanics, IIT Madras, and Dr T. Rajkumar, Professor and Head, Department of Molecular Oncology, Cancer Institute [WIA]

Underfunding from the Department of Science and Technology, Govt. of India, the Department of Molecular Oncology at the Cancer Institute [WIA] had undertaken research to identify proteins that can be detected in the blood which can help in the diagnosis of epithelial ovarian cancers, which accounts for over 90% of the ovarian cancers.

On the other hand, IIT Madras has received funding from Indo-German Science and Technology Centre (IGSTC), DST- Science and Engineering Research Board (SERB) and Indo-US Science and Technology Forum (IUSSTF) to develop point-of-care diagnostic platforms for pathogen detection and disease diagnosis. Novel diagnostic device technologies for important diseases specific to India. In particular, tuberculosis and COVID-19  are at the pre-clinical validation stage. 

Both Institutions will establish a review board and will obtain the necessary ethical clearances to evaluate and review the progress arising from this collaboration. The Cancer Institute (WIA) at Adyar is a comprehensive cancer centre with a hospital, a Research Centre, a Centre for preventive oncology, Epidemiology and Cancer Registry and a College of Oncological Sciences. Its Research centre is engaged in research and development in Molecular Oncology and is further involved in identifying biomarkers for early diagnosis, prognosis and in the development of newer therapeutics in the field of Oncology.

The Key Outcomes envisaged from this collaboration include:

  • Point of care device for early diagnosis of epithelial ovarian cancers
  • A cost-effective and fast method of analysis, using only blood samples allowing out-patient diagnosis.
  • Additional areas of collaboration in the pipeline including early diagnosis of breast cancer [patent filed by Cancer Institute [WIA] and awaiting the publication of the scientific data] and development of a nano-formulation of a peptide [discovered by the team in Cancer Institute for targeting an aggressive bone cancer called Ewing’s sarcoma, patent filed and data published].



Around The World

Our Publications

Advertisement